Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1132563

	registered interest
	date	17/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medicine: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment of the effect on the UK's future participation in future EU Research Programmes in (a) medical research and (b) drugs of the UK leaving the EU without a deal.
	tabling member constituency	Mid Sussex
	tabling member printed	Sir Nicholas Soames
	uin	265405
	answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>Leaving the European Union with a deal remains the Government’s priority. However, as a responsible Government, we must plan for every eventuality, including ‘no deal’.</p><p>The United Kingdom and the EU have a long record of jointly tackling global challenges, with strong existing links already in place between our research and innovation communities, and we want to continue this important collaboration in science, research and innovation, including in medical research.</p><p>The Government is committed to continuing to back UK researchers and innovators by supporting measures to enable world-class collaborative research, including support for small businesses. The Department for Business, Energy and Industrial Strategy is working with the National Academies, the devolved administrations and UK Research and Innovation to develop ambitious and credible alternatives to association, through which we will enable world class collaborative research.</p><p>In addition, earlier in the year, the Minister of State for Universities, Science, Research and Innovation (Chris Skidmore MP) commissioned Sir Adrian Smith to provide independent advice on international collaboration – specifically on potential future UK funding schemes in the context of the UK’s future ambitions for European and international collaboration on research and innovation. His advice will help set the direction for the implementation of the Government’s ambition to ensure the UK continues to be a global leader in science, research and innovation, and an attractive country for individuals to study and work.</p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 20/06/2019 15:30:04 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	116 label Biography information for Lord Soames of Fletching

1132564

	registered interest
	date	17/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Clinical Trials: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what effect the UK leaving the EU without a deal will have on funding of clinical drug trials; if he will make a statement.
	tabling member constituency	Mid Sussex
	tabling member printed	Sir Nicholas Soames
	uin	265406
	answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The United Kingdom and the European Union have a long record of jointly tackling global challenges, with strong existing links already in place between our research and innovation communities, and we want to continue this important collaboration in science, research and innovation.</p><p>The UK and the EU have agreed a flexible extension of the Article 50 period to 31 October 2019. During this extension period the UK will remain a member of the EU, with all the relevant rights and obligations. This means that the UK will continue to participate in Horizon 2020, the EU’s flagship research and innovation programme, on a Member State basis. Further, this extension period provides time for the Government to seek a deal which will ensure the smooth and orderly withdrawal from the EU. If ratified, the proposed Withdrawal Agreement would ensure that following exit the UK could continue to participate in EU programmes such as Horizon 2020 for the lifetime of projects. Further updates on Horizon 2020 planning will be provided in due course.</p><p>As a responsible Government, we are continuing to prepare for all scenarios. In the event that the UK leaves the EU without a deal at the end of this extension period, the Government has confirmed that the funding commitments made under the guarantee and the extension still stand. Through these commitments, the Government will underwrite funding for all successful competitive eligible UK bids to Horizon 2020 that are submitted before the end of the Programme. This guarantee will apply for the lifetime of projects and will provide funding for UK participation in pioneering Horizon 2020 medical research projects can continue.</p><p>Aside from our preparations for leaving the EU, the Government has demonstrated its commitment to research and innovation, including clinical drug trials, by putting it at the heart of its Industrial Strategy, setting an ambition to increase UK total research and development expenditure to 2.4% of gross domestic product by 2027. As a first step towards that we have invested an extra £7 billion in research and development up to 2021/2022. The Government invests over £1 billion in health research through the National Institute for Health Research. This provides direct funding for clinical trials and also the skills, facilities and infrastructure to undertake clinical trials in the health and care service funded by public, charity and industry funders.</p><p> </p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 20/06/2019 15:31:03 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	116 label Biography information for Lord Soames of Fletching

1132476

	registered interest
	date	17/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Reciprocal Arrangements
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the Government will extend the commitment to reimburse EU Member States for the cost of providing healthcare to UK nationals in the event that the UK leaves the EU without a deal and until the UK has secured a reciprocal healthcare agreement with the respective member state which provides for the reimbursement of costs.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Tom Brake
	uin	265407
	answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The United Kingdom Government has proposed to European Union Member States that, in a no-deal scenario, we should maintain the existing healthcare arrangements until 31 December 2020, with the aim of minimising disruption to UK nationals’ and EU citizens’ healthcare provision. This is subject to negotiations, which are ongoing. For UK nationals that live in EU Member States, the UK cannot unilaterally guarantee the continuation of current arrangements, as this depends on decisions by Member States.</p><p>Individuals are always responsible for ensuring they have sufficient healthcare insurance. Anyone who is living, working or studying in EU Member States should check the country specific guidance on GOV.UK and NHS.UK for updates.</p><p><br> The UK Government has committed to fund healthcare for UK nationals (and others for whom the UK is responsible) who have applied for, or are undergoing, treatments in the EU prior to and on exit day, for up to one year, to protect the most vulnerable.</p><p><strong> </strong></p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 20/06/2019 10:29:30 answering member 1585 label Biography information for Stephen Hammond
	tabling member	151 label Biography information for Tom Brake

1132462

	registered interest
	date	17/06/2019
	answering body	Department for International Development
	answering dept id	20
	answering dept short name	International Development
	answering dept sort name	International Development
	hansard heading	Palestinian Authority: Pay
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for International Development, pursuant to the Answer of 11 June 2019 to Question 261075, whether the wages of any UK-funded Palestinian Authority public servants have been reduced as a result of Palestinian Authority spending cuts.
	tabling member constituency	Enfield North
	tabling member printed	Joan Ryan
	uin	265408
	answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>DFID officials are aware that the Palestinian Authority (PA) has begun to make partial salary payments to public sector officials earning 2,000 NIS (£425) or above a month and can confirm that this includes health and education sector public servants whose salaries are funded through UK aid. The UK continues to support a stable PA which can act as an effective partner for peace with Israel. UK aid to the PA’s health and education sectors is used exclusively to pay the salaries of vetted health and education public servants, including teachers, doctors and nurses, in the West Bank. The EU vets the list of PA health and education sector employees before every disbursement of financial aid to ensure only eligible beneficiaries receive UK aid, at a range of grades based on the PA payroll system. These payments are then independently audited. The PA’s decision to make partial salary payments to public sector officials does not affect the robust financial safeguards that ensure UK financial aid reaches its intended beneficiaries.</p> answering member constituency South West Wiltshire answering member printed Dr Andrew Murrison question first answered 20/06/2019 16:14:07 answering member 1466 label Biography information for Dr Andrew Murrison
	tabling member	166 label Biography information for Joan Ryan

1132545

	registered interest
	date	17/06/2019
	answering body	Department for International Development
	answering dept id	20
	answering dept short name	International Development
	answering dept sort name	International Development
	hansard heading	Emergencies: Crimes of Violence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for International Development, what assessment his Department has made of the implications for its policies of the recent Ending Sexual and Gender-based Violence in Humanitarian Crises Conference.
	tabling member constituency	Liverpool, West Derby
	tabling member printed	Stephen Twigg
	uin	265411
	answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>Participants at the Ending Sexual and Gender-Based Violence (SGBV) in Humanitarian Crises Conference agreed that strengthening SGBV prevention and response must be a humanitarian priority. Baroness Sugg represented the UK at the conference and reiterated the UK’s strong leadership on ending all forms of SGBV, announcing UK political commitments which included ensuring access to life-saving sexual and reproductive health services for women and girls in humanitarian crises and £7 million of support to tackle SGBV in Syria through our partnership with the United Nations Population Fund (UNFPA).</p><p> </p><p>The UK reaffirmed our commitments made under the Call to Action on Protection from Gender Based Violence in Emergencies. These commitments are in line with DFID policy.</p> answering member constituency South West Wiltshire answering member printed Dr Andrew Murrison question first answered 20/06/2019 16:21:43 answering member 1466 label Biography information for Dr Andrew Murrison
	tabling member	167 label Biography information for Stephen Twigg

1132546

	registered interest
	date	17/06/2019
	answering body	Department for International Development
	answering dept id	20
	answering dept short name	International Development
	answering dept sort name	International Development
	hansard heading	Emergencies: Crimes of Violence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for International Development, if his Department will commit to increasing funding for gender-based violence services at the Preventing sexual violence initiative conference in November.
	tabling member constituency	Liverpool, West Derby
	tabling member printed	Stephen Twigg
	uin	265412
	answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>There is more the UK can do to prevent all forms of violence, including sexual violence in conflict. Through initiatives such as Preventing Sexual Violence in Conflict (PSVI) and the Ending Sexual and Gender-Based Violence (GBV) in Humanitarian Crises Conference (Oslo Conference) we are continually challenging ourselves and others to step up and do more to tackle the problem.</p><p> </p><p>At the Oslo Conference the UK announced an additional £7 million in funding for GBV in Syria. We are committed to continuing to step up our GBV prevention and response but these efforts are not limited to DFID funding. UK leadership includes advocating for all humanitarian actors to recognise SGBV as a shared priority and investing in evidence that demonstrates both the scale of the problem and effective interventions to address SGBV. We are committed to continuing to invest in ground-breaking programmes such as DFID’s ‘What Works to Prevent Violence’ that provide vital support to women and girls and inform global evidence on the prevalence, severity and effective interventions to prevent violence.</p> answering member constituency South West Wiltshire answering member printed Dr Andrew Murrison question first answered 20/06/2019 16:19:40 answering member 1466 label Biography information for Dr Andrew Murrison
	tabling member	167 label Biography information for Stephen Twigg

1132425

	registered interest
	date	17/06/2019
	answering body	Department for Environment, Food and Rural Affairs
	answering dept id	13
	answering dept short name	Environment, Food and Rural Affairs
	answering dept sort name	Environment, Food and Rural Affairs
	hansard heading	Eels: Smuggling
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Environment, Food and Rural Affairs, what additional steps he plans to take to tackle the illegal trade in eels and elvers.
	tabling member constituency	Stroud
	tabling member printed	Dr David Drew
	uin	265415
	answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The Government takes the issue of illegal trade in eels very seriously and is keen to ensure that at all stages of development – glass eel, elver, or mature eel - they are appropriately protected.</p><p> </p><p>The glass eel fishery in England is highly regulated, and we remain confident we have a good traceability of the catch from the riverbank to the point of export. All known exports of catch from the UK glass eel fishery in recent years have been destined for the known legal market in the EU for restocking and aquaculture.</p><p> </p><p>Moreover, the UK continues to contribute to and support Operation Lake – Europol’s operation to tackle illegal eel trafficking across international borders. We work closely with our European and other international partners in a number of international fora, such as the Convention on International Trade in Endangered Species (CITES), to ensure we are taking strong and effective measures to deter any illegal trade.</p><p> </p><p> </p> answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey question first answered 20/06/2019 09:49:39 answering member 4098 label Biography information for Dr Thérèse Coffey
	tabling member	252 label Biography information for Dr David Drew

1132599

	registered interest
	date	17/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Out-patients: Attendance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the cost to the public purse of missed (a) GP and (b) hospital appointments.
	tabling member constituency	Tewkesbury
	tabling member printed	Mr Laurence Robertson
	uin	265416
	answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>Information surrounding the cost of missed general practitioner and hospital appointments is not collected or held centrally.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 20/06/2019 09:32:08 answering member 4455 label Biography information for Seema Kennedy
	tabling member	253 label Biography information for Mr Laurence Robertson

1132403

	registered interest
	date	17/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what contingency plans his Department has put in place in the event that Vertex declines NHS England’s latest offer for the supply of Orkambi.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	265417
	answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 265418 question first answered 20/06/2019 09:33:36 answering member 4455 label Biography information for Seema Kennedy
	tabling member	298 label Biography information for Steve McCabe

1132404

	registered interest
	date	17/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor: Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of launching a large scale clinical trial of the generic version of Orkambi.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	265418
	answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 265417 question first answered 20/06/2019 09:33:36 answering member 4455 label Biography information for Seema Kennedy
	tabling member	298 label Biography information for Steve McCabe